ArticleCureus2026
Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide 1 (GLP-1) agonists continue to gain popularity in treating an increasing number of chronic conditions. As such, it is imperative that providers keep a vigilant eye on patients utilizing these medicines, monitoring for both known and novel side effects. Herein, we present the case of a patient who developed a rash with features characteristic of acute generalized exanthematous pustulosis (AGEP) one month after increasing her dose of semaglutide (Ozempic®). Her eruption occurred outside of the normal timeline for AGEP but had phenotypic and histopathologic findings consistent with this condition, emphasizing the need for providers to maintain a broad differential when assessing cutaneous eruptions. In addition, this case represents the need to do a thorough ingredient analysis when investigating new symptoms, as it was elucidated that her reaction was likely due to the excipient propylene glycol rather than the active ingredient in semaglutide (Ozempic®). The safety of patients using semaglutide requires close correlation of clinical presentation, histopathologic findings, and multidisciplinary collaboration with pharmacists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.